Sharemaestro Newsreel

Organigram Global Raises FY26 Revenue Guidance Above Estimates

Organigram Global has raised its revenue guidance for fiscal year 2026, now expecting to exceed $255.197 million, which is above the prior market estimate of $241.360 million. This upward revision reflects strong operational performance and positive market sentiment within the cannabis sector, indicating robust …

Stocks Mostly Up Pre-Bell as Investors Assess Uncertainty Over US-Iran Deal

wall street stock market flag new york trading equity -Shutterstock US equity markets were mostly trending higher before the open Tuesday as investors weigh fading optimism that the US and Iran would reach a quick resolution to their conflict and reopen the Strait of …

Organigram Global (OGI) posts 49% revenue growth and big Q3 revaluation gain

Organigram Global Inc. (OGI) reported strong Q3 Fiscal 2026 results, with net revenue increasing 49% to $105.8 million, largely driven by the acquisition of Germany-based Sanity Group and higher Canadian recreational sales. The company posted a net income of $105.5 million, primarily due to …

Incannex Receives Additional A$5.1 Million R&D Tax Incentive Refund, Completing More Than A$11.2 Million in Non-Dilutive Capital Received in 2026

Incannex Healthcare Inc. announced it has received an additional A$5.1 million R&D Tax Incentive refund, bringing its total non-dilutive capital received in 2026 to over A$11.2 million. This refund strengthens the company's financial position and provides flexibility to advance its clinical pipeline, including key …

Incannex receives A$5.1M final R&D refund, totaling A$11.2M non-dilutive funding

Incannex Healthcare (IXHL) has received a final A$5.1 million R&D tax incentive refund, bringing its total non-dilutive funding for 2026 to over A$11.2 million. This significant capital influx strengthens the company's cash position and debt-free balance sheet, providing financial flexibility to advance key clinical …

Stocks making the biggest moves premarket: Riot Platforms, Hims & Hers Health, Intel & more

Check out the companies making the biggest moves premarket: Intel – The chipmaker fell slightly after upsizing a common stock offering to $20 billion from $15 billion. The proceeds, Intel said, would be used for " general corporate purposes ." Hims & Hers Health …

Hims & Hers Q2 2026 earnings: loss despite revenue beat

Hims & Hers Health reported a net loss of $86.3 million in the second quarter of 2026, swinging from net income of $42.5 million in the same period a year earlier, even as revenue climbed 38% to $753.2 million. The company raised its full-year …

TKNO Looks 52.0% Overvalued on GF Value™

Alpha Teknova Inc (NASDAQ: TKNO) has been upgraded to a Buy rating by BTIG with an $8 price target, following a strong Q2 performance and improved funding in the life sciences sector. Despite this, GuruFocus's GF Value™ metric suggests TKNO is approximately 52.0% overvalued, …

Evotec SE expected to post a loss of 9 cents a share - Earnings Preview

Evotec SE is projected to report a loss of 9 cents per share, according to this earnings preview. The article, sourced from Reuters via TradingView News, provides an outlook on the company's financial performance.

BioXcel Therapeutics Amends Oaktree Credit Pact, Extends Deal Deadline and Lowers Liquidity Floor

BioXcel Therapeutics has amended its credit agreement with Oaktree, extending the deadline to secure refinancing or alternative capital to August 21, 2026. The amendment also reduces the minimum liquidity covenant from $6.25 million to $3.0 million, providing the company with more time and financial …

BioXcel Therapeutics (BTAI) cuts liquidity covenant, faces August 2026 refinancing deadline

BioXcel Therapeutics (BTAI) has amended its Credit Agreement, extending its refinancing deadline to August 21, 2026, and reducing its minimum liquidity covenant from $6.25 million to $3.0 million. This amendment gives the company more time to secure financing or strategic options and eases its …

AST SpaceMobile, Intel, On, Rocket Lab, and More Stocks That Explain Today’s Market

Stocks looked set to struggle for direction on Tuesday as investors worried about inflation, with hopes of Iran agreeing a deal to reopen the crucial Strait of Hormuz shipping route fading fast. Continue Reading

Harrow, Inc. (NASDAQ:HROW) Receives Average Recommendation of "Moderate Buy" from Analysts

Harrow, Inc. (NASDAQ:HROW) has received an average rating of "Moderate Buy" from analysts, with eight out of eleven recommending a "buy" and an average 12-month price target of $69.43, significantly higher than its current price of $40.70. Despite falling short on profitability in recent …

Colorado Palisade peaches become Breckenridge's 72-proof whiskey

Tilray Brands' subsidiary, Breckenridge Distillery, has launched a new Breckenridge Peach Whiskey, made with locally sourced Colorado Palisade peaches. This 72-proof flavored whiskey, available now in Colorado and planned for wider national distribution in Fall 2026, features aromas of ripe white peaches with vanilla …

BTIG upgrades Alpha Teknova stock rating on improving fundamentals

BTIG has upgraded Alpha Teknova Inc. (NASDAQ:TKNO) from Neutral to Buy, setting a price target of $8.00, following strong second-quarter 2026 results that exceeded revenue and earnings expectations. The company also raised its 2026 revenue guidance due to improved business fundamentals and a better …

Curaleaf looks to buy Aurora Cannabis, takes bid directly to shareholders

Curaleaf Holdings Inc. announced its intention to launch a takeover bid for Edmonton-based Aurora Cannabis Inc. after private negotiation attempts failed. Curaleaf plans to offer US$4.00 per share plus US$0.75 cash for each Aurora share, a proposal that analysts believe undervalues Aurora's long-term potential. …

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Receives Average Recommendation of "Reduce" from Analysts

Amphastar Pharmaceuticals (NASDAQ:AMPH) has received an average "Reduce" recommendation from eight brokerages, with two analysts rating it a "sell" and six a "hold." Despite this cautious sentiment and an average 12-month price target of $22.00, the company recently surpassed earnings expectations, reporting $0.91 EPS …

Citius Oncology (CTOR) Expected to Announce Earnings on Tuesday

Citius Oncology (NASDAQ:CTOR) is anticipated to release its Q3 2026 earnings before market open on Tuesday, August 18th, with analysts forecasting a loss of $0.04 per share and revenue of $5.83 million. The upcoming earnings call is scheduled for August 21st. The company's previous …

The Technical Signals Behind (HIMS) That Institutions Follow

The article analyzes Hims & Hers Health Inc. (HIMS) using AI models to identify technical signals and institutional trading strategies. It highlights a near-term strong sentiment for HIMS that could challenge persistent mid and long-term weakness, noting resistance testing and a significant risk-reward short …

Organigram Global (NASDAQ:OGI): What Could Today’s Update Reveal About Canadian Cannabis Demand And Integration?

Organigram Global (NASDAQ:OGI) is scheduled to release a quarterly update today. This update is expected to provide insights into Canadian cannabis demand, the quality of this demand, and the company's ability to translate its operating priorities into sustained performance. The key themes revolve around …

Canopy Growth: Penny Stock Purgatory -- or Cannabis Rebound in the Making?

Canopy Growth (NASDAQ: CGC) has spent the better part of the past five years destroying shareholder value. The stock is down more than 99% from its all-time high. The company has burned through billions of dollars, diluted shareholders repeatedly, exited non-core businesses, and cycled …

Sapient Capital LLC Has $1.83 Million Stake in Liquidia Corporation $LQDA

Sapient Capital LLC reduced its stake in Liquidia Corporation by 37.8% during the second quarter, now holding 23,000 shares valued at $1.83 million. Institutional investors collectively own 64.54% of Liquidia, while insiders sold approximately $125.8 million in stock, primarily due to tax obligations. Analysts …

Pacer Advisors Inc. Reduces Stock Holdings in Lantheus Holdings, Inc. $LNTH

Pacer Advisors Inc. significantly reduced its stake in Lantheus Holdings, Inc. by 97.0% in the first quarter, selling 247,589 shares and retaining 7,704 shares valued at $584,000. Despite this, other institutional investors have recently modified their holdings, and 99.06% of the stock is still …

Lantheus Holdings (LNTH) Agreed To Be Acquired, Is The Remaining Upside Already Priced In?

Curium US LLC has agreed to acquire Lantheus Holdings (LNTH) for US$102.50 in cash per share plus contingent value rights up to US$12.00 per share, with the deal expected to close in the first half of 2027. The article discusses whether the remaining upside …

Supernus Pharmaceuticals (SUPN) Stock May Be A Bargain After Merger News

Baylor College of Medicine strikes multimillion-dollar deal with United Therapeutics for transplant center

Baylor College of Medicine and United Therapeutics have signed a multimillion-dollar agreement to establish the Baylor College of Medicine Center for Xenoliver Transplantation and Immunomodulation. This partnership coincides with United Therapeutics' upcoming opening of its nearly $100 million xenotransplantation facility in Houston. The collaboration …

VTRS Q2 Deep Dive: China Growth, Pipeline Progress, and Margin Concerns Shape Outlook

Viatris (VTRS) reported better-than-expected Q2 CY2026 revenue and non-GAAP profit, driven by strong commercial execution in Greater China and demand for cardiovascular products. Despite this, the company faced a negative market reaction due to supply chain disruptions and lower-margin products in emerging markets. Management …

Renaissance Technologies LLC Buys 120,188 Shares of BioAge Labs, Inc. $BIOA

Renaissance Technologies LLC significantly increased its stake in BioAge Labs, Inc. (NASDAQ:BIOA) by 653.2% in the first quarter, acquiring an additional 120,188 shares, bringing its total to 138,588 shares valued at approximately $2.42 million. Other institutional investors also added to their positions. Despite reporting …

Renaissance Technologies LLC Has $2.17 Million Stake in Prestige Consumer Healthcare Inc. $PBH

Renaissance Technologies LLC significantly reduced its stake in Prestige Consumer Healthcare Inc. (PBH) by 62% in the first quarter, selling 59,900 shares but retaining 36,702 shares valued at approximately $2.17 million. Despite this, institutional investors collectively own 99.95% of PBH. Prestige Consumer Healthcare reported …

Quantinno Capital Management LP Acquires 19,281 Shares of Prestige Consumer Healthcare Inc. $PBH

Quantinno Capital Management LP significantly increased its stake in Prestige Consumer Healthcare Inc. (PBH) by acquiring 19,281 shares, bringing its total holdings to 36,990 shares valued at $2.19 million. Institutional investors collectively own 99.95% of PBH. The company also surpassed quarterly earnings expectations, reporting …

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Given Average Rating of "Moderate Buy" by Brokerages

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) has received a "Moderate Buy" consensus rating from ten research firms, with an average 12-month price target of $42.00. Several brokerages recently raised their price targets for Teva. The company's shares opened at $36.04, near their 52-week high, and …

SCYNEXIS Inc (SCYX) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for SCYNEXIS Inc (SCYX), highlighting its current earnings forecast score, analyst ratings, and price targets. Based on 3 analysts, the stock has an average price target of $4.00 and a "Buy" trend. The report also details past and …

United Therapeutics’s Q2 Earnings Call: Our Top 5 Analyst Questions

Hims & Hers anticipates $880M-$900M Q3 revenue while raising 2026 outlook to $3.1B-$3.3B

Earnings Call Insights: Hims & Hers Health (HIMS) Q2 2026 MANAGEMENT VIEW * "In the second quarter, we welcomed more than 300,000 subscribers, bringing our global subscriber base to nearly 3 million people." (Co-Founder, Chairman & CEO Andrew Dudum) * "In June, we became …

Prestige Consumer Healthcare (PBH) Is Up 5.6% After Raising Fiscal 2027 Outlook on Acquisitions

Prestige Consumer Healthcare (PBH) saw its stock rise by 5.6% after reporting its fiscal 2027 first-quarter results and subsequently raising its full-year outlook. The company's updated revenue guidance of US$1.29 billion–US$1.32 billion and GAAP diluted EPS guidance of US$4.18–US$4.28 are primarily driven by recent …

Viatris (VTRS) Stock Trades At A Discount To Sales Despite A 76% Run

Viatris (VTRS) stock has seen a 76.1% gain over the past year, yet remains undervalued according to various valuation checks, trading at a discount to sales compared to its industry peers. The recent FDA approval for Gwyn Lo contraceptive patch and the planned sale …